US6107499A
(en)
*
|
1988-02-26 |
2000-08-22 |
Neuromedica, Inc. |
Dopamine analog amide
|
US6576636B2
(en)
*
|
1996-05-22 |
2003-06-10 |
Protarga, Inc. |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
|
US5795909A
(en)
*
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
US6153653A
(en)
*
|
1997-11-26 |
2000-11-28 |
Protarga, Inc. |
Choline compositions and uses thereof
|
US5977174A
(en)
*
|
1997-11-26 |
1999-11-02 |
Neuromedica, Inc. |
Cholinergic compositions and uses thereof
|
US5955459A
(en)
*
|
1997-11-26 |
1999-09-21 |
Neuromedica, Inc. |
Fatty acid-antipsychotic compositions and uses thereof
|
US6197764B1
(en)
|
1997-11-26 |
2001-03-06 |
Protarga, Inc. |
Clozapine compositions and uses thereof
|
US6579551B1
(en)
|
1998-05-21 |
2003-06-17 |
Beech-Nut Nutrition Corporation |
Baby-food compositions containing egg yolk and methods therefor
|
US6149964A
(en)
*
|
1998-05-21 |
2000-11-21 |
Beech-Nut Nutrition Corporation |
Egg yolk-containing baby food compositions and methods therefor
|
US7413759B2
(en)
*
|
1998-05-21 |
2008-08-19 |
Beech-Nut Nutrition Corporation |
Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
|
US7141266B2
(en)
*
|
1998-05-21 |
2006-11-28 |
Beech-Nut Nutrition Corporation |
Baby-food compositions enhancing visual acuity and methods therefor
|
US5892068A
(en)
*
|
1998-08-25 |
1999-04-06 |
Mcneil-Ppc, Inc. |
Preparation of sterol and stanol-esters
|
NZ333817A
(en)
*
|
1998-08-25 |
2000-09-29 |
Mcneil Ppc Inc |
Process for preparing stanol/sterol fatty acid esters such as beta sitosterol fatty acid esters, useful in reducing cholesterol levels
|
GB9901809D0
(en)
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
AU2006201772B2
(en)
*
|
1999-01-27 |
2010-02-04 |
Amarin Neuroscience Limited |
Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
|
US7235583B1
(en)
*
|
1999-03-09 |
2007-06-26 |
Luitpold Pharmaceuticals, Inc., |
Fatty acid-anticancer conjugates and uses thereof
|
EP1175901B1
(en)
*
|
1999-04-15 |
2006-05-31 |
Kaneka Corporation |
Peroxisome activator-responsive receptor agonists
|
CA2382262C
(en)
*
|
1999-08-30 |
2004-12-07 |
Ocean Nutrition Canada Ltd. |
A nutritional supplement for lowering serum triglyceride and cholesterol levels
|
US6998501B1
(en)
*
|
1999-08-30 |
2006-02-14 |
Ocean Nutrition Canada Limited |
Nutritional supplement for lowering serum triglyceride and cholesterol levels
|
US20030206958A1
(en)
*
|
2000-12-22 |
2003-11-06 |
Cattaneo Maurizio V. |
Chitosan biopolymer for the topical delivery of active agents
|
ATE384518T1
(de)
*
|
2000-01-31 |
2008-02-15 |
Haerting S A |
Zusammensetzungen enthaltend phytosterol- und policosanolester von fettsäuren zur herabsetzung des cholesterol- und triglyceridspiegels
|
KR20010091499A
(ko)
*
|
2000-03-16 |
2001-10-23 |
김용범 |
레이저 그래픽 디스플레이 장치
|
EP1427407A4
(en)
|
2001-03-23 |
2005-05-11 |
Luitpold Pharm Inc |
CONJUGATES BASED ON FATTY AMINES AND PHARMACEUTICAL AGENTS
|
EP1423107B1
(en)
*
|
2001-03-23 |
2012-05-09 |
Luitpold Pharmaceuticals, Inc. |
Fatty alcohol drug conjugates
|
JP2003048831A
(ja)
*
|
2001-08-02 |
2003-02-21 |
Suntory Ltd |
脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
|
DE10154221A1
(de)
*
|
2001-11-07 |
2003-05-15 |
Max Delbrueck Centrum |
Mittel zur Behandlung von Läsionen des Nervensystems
|
US20050123500A1
(en)
*
|
2003-01-31 |
2005-06-09 |
The Procter & Gamble Company |
Means for improving the appearance of mammalian hair and nails
|
JP2006524187A
(ja)
*
|
2003-01-31 |
2006-10-26 |
ザ プロクター アンド ギャンブル カンパニー |
哺乳類のケラチン組織の外観を改善する手段
|
EP1637134A4
(en)
*
|
2003-06-20 |
2010-01-27 |
Mochida Pharm Co Ltd |
COMPOSITION FOR THE PREVENTION AND TREATMENT OF VARICES
|
CA2436650A1
(en)
*
|
2003-08-06 |
2005-02-06 |
Naturia Inc. |
Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
|
US20060141046A1
(en)
*
|
2004-05-06 |
2006-06-29 |
Ivrea Pharmaceuticals, Inc. |
Particles for the delivery of active agents
|
CA2565236A1
(en)
*
|
2004-05-06 |
2005-11-17 |
Ivrea Pharmaceuticals, Inc. |
Particles for the delivery of active agents
|
AU2006269405B2
(en)
*
|
2005-07-08 |
2013-01-17 |
Dsm Ip Assets B.V. |
Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
|
US20080110624A1
(en)
*
|
2005-07-15 |
2008-05-15 |
Halliburton Energy Services, Inc. |
Methods for controlling water and particulate production in subterranean wells
|
ITMI20052377A1
(it)
*
|
2005-12-13 |
2007-06-14 |
Anna Petroni |
Medicamento a base di monoestere di steroidi con acidi grassi a catena lunga
|
FR2902659A1
(fr)
*
|
2006-06-23 |
2007-12-28 |
Pierre Fabre Medicament Sa |
Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
|
EP3578177A1
(en)
|
2008-09-02 |
2019-12-11 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
|
PT2395991E
(pt)
|
2009-02-10 |
2013-09-03 |
Amarin Pharmaceuticals Ie Ltd |
Utilização de éster etílico de ácido eicosapentaenóico para tratamento de hipertrigliceridemia
|
NZ789295A
(en)
|
2009-04-29 |
2024-02-23 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
NZ627238A
(en)
|
2009-04-29 |
2016-02-26 |
Amarin Pharmaceuticals Ie Ltd |
Stable pharmaceutical composition comprising ethyl eicosapentaenoate
|
CN114053258A
(zh)
|
2009-06-15 |
2022-02-18 |
阿马里纳药物爱尔兰有限公司 |
在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
|
SG10201405994UA
(en)
|
2009-09-23 |
2014-10-30 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
|
WO2011053048A2
(ko)
*
|
2009-10-29 |
2011-05-05 |
연세대학교 산학협력단 |
신규 혈관누출 차단제
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
NZ778131A
(en)
|
2010-11-29 |
2023-03-31 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
WO2013070735A1
(en)
|
2011-11-07 |
2013-05-16 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
AU2013207368A1
(en)
|
2012-01-06 |
2014-07-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
|
JP2015522029A
(ja)
|
2012-06-29 |
2015-08-03 |
アマリン ファーマシューティカルス アイルランド リミテッド |
スタチン療法中の患者における心血管系イベントの危険性を減少させる方法
|
US9717741B2
(en)
|
2012-10-11 |
2017-08-01 |
Anaplasi Pharmaceuticals Llc |
Method and compositions for treating psoriasis
|
JP6059352B2
(ja)
*
|
2012-10-11 |
2017-01-11 |
アナプラシ ファーマシューティカルズ エルエルシー |
乾癬を治療するための方法及び組成物
|
US20150265566A1
(en)
|
2012-11-06 |
2015-09-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
US10172818B2
(en)
|
2014-06-16 |
2019-01-08 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
JP6224203B2
(ja)
*
|
2016-12-08 |
2017-11-01 |
アナプラシ ファーマシューティカルズ エルエルシー |
乾癬を治療するための組成物
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
JP6491293B2
(ja)
*
|
2017-10-04 |
2019-03-27 |
アナプラシ ファーマシューティカルズ エルエルシー |
乾癬を治療するためのエアロゾル、ムース、又はフォームの組成物
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
CN112218630A
(zh)
|
2018-09-24 |
2021-01-12 |
阿马里纳药物爱尔兰有限公司 |
降低受试者的心血管事件的风险的方法
|
JP6728425B2
(ja)
*
|
2019-02-28 |
2020-07-22 |
アナプラシ ファーマシューティカルズ エルエルシー |
乾癬を治療するためのクリーム、ローション、又はゲルの組成物
|
WO2022225896A1
(en)
|
2021-04-21 |
2022-10-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|